The Valley Desk

ArticleJournal of thoracic diseasePublished

Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Hospital of the University of Pennsylvania, with Penn Medicine linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Journal of thoracic disease
Published
Subject terms
Non-small cell lung cancer (NSCLC); Afatinib; Epidermal Growth Factor Receptor Mutations (Egfr Mutations); Osimertinib; Egfr Tyrosine Kinase Inhibitor (Egfr Tki)
PubMed ID
38090314
PubMed Central ID
PMC10713299
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal